These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38213955)

  • 1. Omeprazole Induced Rapid Drug Reaction with Eosinophilia, Systemic Symptoms, and Cross-Reactivity in Delayed-Type Hypersensitivity Associated with Proton-Pump Inhibitors: A Case Report and Literature Review.
    Pinyopornpanish K; Pinyopornpanish K; Pinyopornpanish K; Benjanuwattra J; Teepapan P; Chungcharoenpanich A; Laisuan W
    Case Reports Immunol; 2024; 2024():1317971. PubMed ID: 38213955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity.
    Kepil Özdemir S; Yılmaz I; Aydin Ö; Büyüköztürk S; Gelincik A; Demirtürk M; Erdoğdu D; Cömert S; Erdoğan T; Karakaya G; Kalyoncu AF; Oner Erkekol F; Dursun AB; Misirligil Z; Bavbek S
    Allergy; 2013 Aug; 68(8):1008-14. PubMed ID: 23895584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug rash with eosinophilia and systemic symptoms and severe renal injury induced by proton pump inhibitor therapy: A case report.
    He Q; Ying G; Fei X; Zha C; Chen Z; Bao Y; Long J; Wang Z; He X; Xia M
    Medicine (Baltimore); 2020 Oct; 99(42):e22509. PubMed ID: 33080685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study.
    Lin CY; Wang CW; Hui CR; Chang YC; Yang CH; Cheng CY; Chen WW; Ke WM; Chung WH
    Allergy; 2018 Jan; 73(1):221-229. PubMed ID: 28658503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark DW; Strandell J
    Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Hypersensitivity Reactions to Proton Pump Inhibitors: A Retrospective Experience.
    Kepil Özdemir S; Öner Erkekol F; Ünal D; Büyüköztürk S; Gelincik A; Dursun AB; Karakaya G; Bavbek S
    Int Arch Allergy Immunol; 2016; 171(1):54-60. PubMed ID: 27838693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole.
    Gouraud A; Vochelle V; Descotes J; Vial T
    Clin Drug Investig; 2010; 30(8):559-63. PubMed ID: 20586518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPI adverse drugs reactions: a retrospective study.
    Casciaro M; Navarra M; Inferrera G; Liotta M; Gangemi S; Minciullo PL
    Clin Mol Allergy; 2019; 17():1. PubMed ID: 30675130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
    Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
    Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate-Type Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the French National Pharmacovigilance Database.
    Tourillon C; Mahe J; Baron A; Lambert A; Yélehé-Okouma M; Veyrac G; Jolliet P
    Int Arch Allergy Immunol; 2019; 178(2):159-166. PubMed ID: 30485850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
    Lu S; Zhao J; Chen X; Xu S; Yang X; Zhang Y; Ma Z; Jiang H; Zhou H
    Chem Biol Interact; 2022 Dec; 368():110219. PubMed ID: 36243147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.
    Ahn N; Wawro N; Baumeister SE; Nolde M; Gerlach R; Tauscher M; Günter A; Güntner F; Rückert-Eheberg IM; Meisinger C; Linseisen J
    Drugs Aging; 2023 Jul; 40(7):653-663. PubMed ID: 37178361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A; Bacon T; Peterson M
    J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.